Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response.

Slides:

Advertisements

Similar presentations

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Advertisements

Manuel J. Antunes, MD, PhD, DSc

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

Stephen R. Broderick, MD, MPHS

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Mitral stenosis with pulmonary hypertension: We should operate early

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

The effect of center volume on the incidence of postoperative complications and their impact on survival after lung transplantation Arman Kilic, MD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

Pleomorphic carcinoma of the lung: A surgical outcome

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience Maria Teresa Congedo, MD, Alfredo Cesario,

Survival after resection of synchronous non–small cell lung cancer

Complex Esophageal Reconstruction Procedures Have Acceptable Outcomes Compared With Routine Esophagectomy Jessica M. Moore, BS, Craig M. Hooker, PhD,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Supracoronary ascending aortic replacement in patients with acute aortic dissection type A: What happens to the aortic root in the long run? Bartosz.

Application of a neuroscience research model to study neuroprotection in children with congenital heart disease Nobuyuki Ishibashi, MD, Richard A. Jonas,

Outcomes in lung transplantation after previous lung volume reduction surgery in a contemporary cohort Leah Backhus, MD, Jonathon Sargent, BS, Aaron.

How should we treat air leaks?

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Recurrence of mitral regurgitation after partial versus complete mitral valve ring annuloplasty for functional mitral regurgitation Michael H. Kwon,

The lord of the rings Antonio Miceli, MD, PhD

Impact of prior hospital mortality versus surgical volume on mortality following surgery for congenital heart disease Matthew E. Oster, MD, Matthew J.

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Do we need a bibliometrician to know which way the wind is blowing?

Stephen R. Broderick, MD, MPHS

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Niv Ad, MD, Lawrence M. Wei, MD

The unmasking of a Brugada phenotype after pulmonary resection: A case report and implications for postoperative management Saila P. Nicotera, MD, MPH,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Pathologic complete response after esophagectomy following neoadjuvant chemoradiation therapy for esophageal carcinoma: A cure sometimes? Shawn S. Groth,

Pulmonary Resection for Metastases from Colorectal Cancer

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

James I. Fann, MD, John E. Connolly, MD

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Innovation in cardiothoracic surgical training

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Multifocal lung cancer within ground glass lesions: Are favorable outcomes consequent to surgical resection or inherent to the disease? Mara B. Antonoff,

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural.

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

After neoadjuvant chemoradiation therapy, predicted pulmonary function may be reduced by 10% Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular.

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Junaid Haroon, MD, Subroto Paul, MD, MPH

Managing conflicts of interest

First in line for robotic surgery: Would you want to know?

More than vital: Who bears the burden?

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Journal changes and initiatives

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for.

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response and those with partial or no response? Robert A. Meguid, MD, MPH, Craig M. Hooker, MPH, Joshua T. Taylor, BS, Laurence R. Kleinberg, MD, Stephen M. Cattaneo, MD, Marc S. Sussman, MD, Stephen C. Yang, MD, Richard F. Heitmiller, MD, Arlene A. Forastiere, MD, Malcolm V. Brock, MD The Journal of Thoracic and Cardiovascular Surgery Volume 138, Issue 6, Pages 1309-1317 (December 2009) DOI: 10.1016/j.jtcvs.2009.07.069 Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Kaplan-Meier estimates of recurrence-free survival of patients with esophageal cancer (n = 261) at the Johns Hopkins Hospital, according to pathologic response at time of surgical resection. CR, Complete response; NR, nonresponse; PR, partial response. The Journal of Thoracic and Cardiovascular Surgery 2009 138, 1309-1317DOI: (10.1016/j.jtcvs.2009.07.069) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Kaplan-Meier estimates of overall survival of patients with esophageal cancer (n = 267) at the Johns Hopkins Hospital, according to pathologic response at time of surgical resection. The Kaplan-Meier estimates for overall survival indicate that as the extent of pathologic response to neoadjuvant therapy increases, there is a significant increase in the overall survival of the patient. It is interesting to note, however, that in our observed cohort, the degree of pathologic response to neoadjuvant therapy seemed not to affect patients with early mortality (<10 months) but rather those who survived more than 1 year. CR, Complete response; NR, nonresponse; PR, partial response. The Journal of Thoracic and Cardiovascular Surgery 2009 138, 1309-1317DOI: (10.1016/j.jtcvs.2009.07.069) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Kaplan-Meier estimates of overall survival of patients with esophageal cancer who had a complete pathologic response to neoadjuvant therapy (n = 82) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection. D-F, Disease-free; R, recurrence. The Journal of Thoracic and Cardiovascular Surgery 2009 138, 1309-1317DOI: (10.1016/j.jtcvs.2009.07.069) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Kaplan-Meier estimates of overall survival of patients with esophageal cancer who had a partial pathologic response to neoadjuvant therapy (n = 108) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection. D-F, Disease-free; R, recurrence. The Journal of Thoracic and Cardiovascular Surgery 2009 138, 1309-1317DOI: (10.1016/j.jtcvs.2009.07.069) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Kaplan-Meier estimates of overall survival of patients with esophageal cancer who had no pathologic response to neoadjuvant therapy (n = 71) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection. D-F, Disease-free; R, recurrence. The Journal of Thoracic and Cardiovascular Surgery 2009 138, 1309-1317DOI: (10.1016/j.jtcvs.2009.07.069) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions